{"id":8503,"date":"2025-09-05T19:30:08","date_gmt":"2025-09-05T16:30:08","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8503"},"modified":"2025-09-05T19:30:08","modified_gmt":"2025-09-05T16:30:08","slug":"drug-coated-balloons-and-stents-in-pad-limited-impact","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/drug-coated-balloons-and-stents-in-pad-limited-impact\/","title":{"rendered":"Drug-Coated Balloons and Stents in PAD -Limited Impact"},"content":{"rendered":"<div>Drug-Coated Balloons and Stents in PAD -Limited Impact<\/div>\n<div><\/div>\n<div>Source: Medical News, ESC Congress 2025<\/div>\n<div><\/div>\n<div>1- Background<\/div>\n<div><span> \u2022 Drug-coated stents and balloons (mainly paclitaxel-based) reduce restenosis and early reinterventions in PAD.<\/span><\/div>\n<div><span> \u2022 Their impact on key outcomes\u2014quality of life, amputation prevention, and safety\u2014remains uncertain.<\/span><\/div>\n<div><\/div>\n<div>2- SWEDEPAD 1 (CLTI, &gt;2,300 patients)<\/div>\n<div><span> \u2022 Compared paclitaxel-coated vs. uncoated balloons in chronic limb-threatening ischemia.<\/span><\/div>\n<div><span> \u2022 Primary endpoint: time to above-ankle amputation.<\/span><\/div>\n<div><span> \u2022 Findings:<\/span><\/div>\n<div><span> \u2022 No significant difference after 5 years.<\/span><\/div>\n<div><span> \u2022 Early reduction in reinterventions (year 1), but no sustained benefit long term.<\/span><\/div>\n<div><\/div>\n<div>3- SWEDEPAD 2 (Intermittent claudication, &gt;1,100 patients)<\/div>\n<div><span> \u2022 Compared paclitaxel-coated vs. uncoated balloons.<\/span><\/div>\n<div><span> \u2022 Findings after follow-up:<\/span><\/div>\n<div><span> \u2022 No difference in quality of life (12 months).<\/span><\/div>\n<div><span> \u2022 No difference in reintervention (median 6.2 years).<\/span><\/div>\n<div><span> \u2022 No difference in all-cause mortality (median 7.1 years).<\/span><\/div>\n<div><span> \u2022 Higher 5-year mortality in the paclitaxel group.<\/span><\/div>\n<div><\/div>\n<div>4- Key Conclusion<\/div>\n<div><span> \u2022 Paclitaxel-coated devices did not reduce amputations in CLTI or improve quality of life in claudication.<\/span><\/div>\n<div><span> \u2022 Safety concerns remain due to possible increased long-term mortality.<\/span><\/div>\n<div><span> \u2022 Clinicians should balance risks against the high cost before use.<\/span><\/div>\n<div><span> \u2022 Further research is warranted into non-paclitaxel drug-coated technologies.<\/span><\/div>\n<div><a href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT02051088\">https:\/\/www.clinicaltrials.gov\/study\/NCT02051088<\/a><\/div>\n<div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Drug-Coated Balloons and Stents in PAD -Limited Impact Source: Medical News, ESC Congress 2025 1- Background \u2022 Drug-coated stents and balloons (mainly paclitaxel-based) reduce restenosis and early reinterventions in PAD. \u2022 Their impact on key outcomes\u2014quality of life, amputation prevention, and safety\u2014remains uncertain. 2- SWEDEPAD 1 (CLTI, &gt;2,300 patients) \u2022 Compared paclitaxel-coated vs. uncoated balloons [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8503","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8503","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8503"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8503\/revisions"}],"predecessor-version":[{"id":8504,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8503\/revisions\/8504"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8503"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8503"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8503"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}